Archbold Memorial Hospital’s Singletary Oncology Center and the prestigious Winship Cancer Institute of Emory University recently announced a partnership that will enhance access to state-of-the-art cancer research and treatment to patients in Southwest Georgia.
Effective today, Archbold’s Singletary Oncology Center will become the first hospital to join an elite group of community hospitals known as Emory’s Winship Cancer Network.
Winship is the first and only National Cancer Institute-designated cancer center in the state of Georgia. The partnership will compliment an already robust clinical research program at the Singletary Oncology Center—a program that is currently accepting patients for nine of 17 existing clinical trials and registries. Through the partnership with Winship, eligible Archbold oncology patients will now have access to more than 250 existing therapeutic clinical trials and research by top clinicians and researchers from around the world, in many cases without having to travel to metro Atlanta or other large cities for access to cutting edge investigative treatments.
“The clinical research partnership with Emory is such a great thing for patients in our region,” Archbold oncology clinical research director Teresa Coleman, MD. “Our existing program is already very strong and currently offers more trials than any hospital in the South Georgia/North Florida region. Through the Winship network, Archbold oncology patients will now have access to the largest unit in Georgia for phase I clinical trials, which are very important in introducing new therapies against cancer. It’s really incredible what this partnership will mean for patients in our region.”
Archbold physicians and patients will benefit from direct access to Winship’s multidisciplinary cancer meetings for collaboration in cancer treatment. Archbold physicians, nurses, and clinical research staff can also leverage opportunities for specialized training at Winship.
Emory’s Winship Cancer Institute is ranked in the top 25 cancer care centers in the country, according to U.S. News & World Report, and has improved access to high quality cancer care, the newest research and continuing patient and provider education for affiliate partners like Archbold.
“We are very excited to join forces with the excellent physicians and clinical staff at Archbold,” says Walter J. Curran, Jr., MD, Winship’s executive director. “Patients will benefit from access to expedited second opinions for selected patients and to enrollment in selected Winship clinical trials while receiving treatment and therapy through their local doctors close to home.”
“Archbold patients have always had access to state-of-the-art treatments and technology provided by some of the most knowledgeable and dedicated physician specialists in our region,” said Becky Troyer, Singletary Oncology Center administrator. “We’re committed to remaining ahead of the curve and providing the best treatment options for our patients. We have great respect for the research team and physicians at Emory, and the partnership will help us take our already sophisticated clinical trials program to the next level, which will result in many more options for our patients. We’re very proud of what the partnership with Emory will mean to oncology patients in our region.”
The Singletary Oncology Center oncology research team (from left) Tiffany Woolum, RN; Lenore Beckett, RN; Josh Simmons, MD; Teresa Coleman, MD, FACP; and Lisa Speigner, RN.
Effective today, Archbold’s Singletary Oncology Center (pictured above) will become the first hospital to join an elite group of community hospitals known as Emory’s Winship Cancer Network.